{"id":"tp-48205","type":"article-newspaper","title":"Rhythm Pharmaceuticals Expects to Dose First Phase III Patients in January","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/48205","datePublished":"2026-11-04T04:02:07.000Z","dateModified":"2026-11-04T04:02:07.000Z","language":"en","abstract":"The company committed $350 million to a royalty buy-down. CEO David Meeker cited $92 million in third-quarter revenue and called the U.S. launch an “excellent start.”","section":"Business","references":[]}